Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors
Recorded on Tuesday, August 24, 2021
BTK inhibitors have revolutionized the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia. CLL Society worked with Cancer Coach Live and LLS to develop this resource to answer many of the common questions related to BTK inhibitor use and concerns in CLL/SLL. There is also information on Covid vaccinations in CLL including a simple table that details how well CLL patients produce anti SARS-CoV-2 antibodies based on what type of their CLL/SLL therapy they have received.
Speakers include Drs. Matthew Davids and Susan O’Brien and video presentations can be found under Modules.
Emerging Combinations for Newly Diagnosed CLL
High‐Risk Relapsed/Refractory (R/R) CLL